×

Please Remove Adblock
Adverts are the main source of Revenue for DoveMed. Please remove adblock to help us create the best medical content found on the Internet.

MPN1 Mutation Analysis Test

Last updated May 29, 2017

The MPN1 Mutation Analysis Test is a genetic test that helps detect abnormalities in the MPN1 gene. It is used to diagnose poikiloderma with neutropenia.


What are other Names this Test? (Equivalent Terms)

  • C16orf57 Mutation Analysis Test

What is MPN1 Mutation Analysis Test? (Background Information)

  • MPN1 mutation refers to an alteration in the MPN1 gene, which is associated with a condition called poikiloderma with neutropenia
  • The MPN1 gene gives instructions for the MPN1 protein. MPN1 plays a role in the conversion of genetic material to proteins
  • Specifically, MPN1 is required for a process called alternative splicing, whereby the intermediate compound (RNA) formed after DNA is read, but before it is converted to protein, is further modified
  • Alterations in the MPN1 gene may result in an MPN1 protein that is unable to perform its function. This abnormality in MPN1 interferes with alternative splicing and causes problems with the normal process of making proteins from DNA
  • Poikiloderma with neutropenia may be caused by MPN1 mutation. This condition is characterized by skin abnormalities, such as spots of discoloration, as well as respiratory symptoms such as coughing and pneumonia
  • The exact link between abnormal MPN1 and poikiloderma with neutropenia is unknown. However, there is a clear genetic association
  • The MPN1 Mutation Analysis Test is a genetic test that helps detect abnormalities in the MPN1 gene. It is used to diagnose poikiloderma with neutropenia

Molecular testing, in general, can be performed using a variety of methods. Some of these methods include:

  • In situ hybridization techniques, such as fluorescence in situ hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Next-generation sequencing (NGS)
  • Methylation profiling
  • Polymerase chain reaction (PCR)
  • Comparative genomic hybridization (CGH)
  • Karyotyping including spectral karyotyping
  • mRNA analysis
  • Tissue microarrays (TMAs)
  • Southern blot test
  • Northern blot test
  • Western blot test
  • Eastern blot test

The methodology used for the test may vary from one laboratory to another.

Note: Molecular testing has limitations depending on the method being used, and genetic mutational abnormalities being tested. This can affect the results on a case-by-case basis. Consultation with your healthcare provider will help in determining the right test and right molecular method, based on individual circumstances.

What are the Clinical Indications for performing the MPN1 Mutation Analysis Test?

Following are the clinical indications for performing the MPN1 Mutation Analysis Test: 

  • Spots of lighter or darker color on the skin
  • Cough
  • Spot baldness (alopecia) of head and eyebrows
  • Cataracts
  • Skeletal problems

In general, the molecular genetic testing is undertaken in the following situations: 

  • To assist (and in some cases, confirm) the initial diagnosis
  • To check for or ascertain a family history of the condition
  • To distinguish other conditions that have similar features (signs and symptoms)
  • To help determine treatment options

How is the Specimen Collected for MPN1 Mutation Analysis Test?

The type and source and specimen sample requirements will depend on the preference of the individuals and the preference of the testing lab. Thus, it may vary from one individual to another and from one lab to another. Therefore, it is important to contact the testing lab for exact specimen requirements, before initiating the collecting and testing process.

Following is the specimen collection process for MPN1 Mutation Analysis Test:

  • Sample on which the test is performed may include:
    • Peripheral blood in individuals showing signs and symptoms suspected of the condition
    • Bone marrow biopsy specimen
    • For mitochondrial DNA testing, usually a muscle biopsy or a liver biopsy is preferred
    • In case of expectant mothers, prenatal testing through amniotic fluid and chorionic villi sampling
    • Fetal cord blood
    • Fresh tissue from biopsy
    • Fresh tissue from autopsy sample
    • Fresh tissue from fetal demise
    • Buccal brushes: Using the kit that is provided by the testing laboratory, buccal brushes can be used to collect the specimen, by scraping the inner cheek lining (buccal mucosa)
    • Oral rinse specimens
    • Body fluids such as saliva, tears, and semen
    • Dried blood spots: This specimen type is usually requested in situations where the collection and/or shipping of whole blood is not practical
    • In some cases, hair samples (with attached roots), finger nails, and buccal swabs, may be acceptable
    • Formalin-fixed paraffin-embedded solid tumor tissue (FFPE tumor tissue), often referred to as paraffin block of the tumor
    • Products of conception sample from aborted pregnancy
  • Process of obtaining the sample: As outlined by the laboratory testing facility
  • Preparation required: As outlined by the laboratory testing facility

Important information:

Limitations of specimen while testing for the condition

  • For blood specimens: Individuals, who have received platelet transfusions, red blood transfusion, or white blood (leukocyte) transfusion, should wait at least 4 weeks before providing a blood specimen
  • The following specimens may not be acceptable in individuals who have received heterologous bone marrow transplant (in the past):
    • Peripheral blood samples
    • Oral rinse specimens
    • Bone marrow biopsy specimens
  • Testing should not be performed on a transplanted organ/specimen, since the genetic material belongs to the donor and not to the individual being tested
  • Formalin-fixed paraffin-embedded solid tumor tissue: In many cases, FFPE tissue blocks are usually not acceptable. Please contact the testing lab to ascertain, if it is an acceptable sample specimen
  • In some cases, a different source of specimen may be acceptable to the laboratory performing the test

Occasionally, additional samples may be required to either repeat the test or to perform follow-up testing.

Turnaround time for test results

  • Depending on the location of testing, it may take from 2 to 8 weeks from the time of sample collection, to obtain the test results

Sample storage information

  • Many hospitals preserve the paraffin blocks for at least 7 years
  • In general, older paraffin blocks (over 5 years) may affect the detection of specific mutations, due to degradation of the tissue specimen over time

Cost of MPN1 Mutation Analysis Test:

  • The cost of the test procedure depends on a variety of factors, such as the type of your health insurance, annual deductibles, co-pay requirements, whether your healthcare provider/facility is in-network or out-of-network of your insurance company
  • In many cases, an estimate may be provided before the test is conducted. The final amount may depend upon the findings during the test procedure and post-operative care, if required

What is the Significance of the MPN1 Mutation Analysis Test Result?

  • A mutation in the MPN1 gene indicates a positive result for the MPN1 Mutation Analysis Test. This may point to a diagnosis of poikiloderma with neutropenia

The laboratory test results are NOT to be interpreted as results of a "stand-alone" test. The test results have to be interpreted after correlating with suitable clinical findings and additional supplemental tests/information. Your healthcare providers will explain the meaning of your tests results, based on the overall clinical scenario.

Additional and Relevant Useful Information:

  • Poikiloderma with neutropenia is a rare condition studied mainly in individuals of Navajo descent
  • Many laboratories may not have the capability to perform this test. Only highly-specialized labs with advanced facilities and testing procedures may offer this test

Certain medications that you may be currently taking may influence the outcome of the test. Hence, it is important to inform your healthcare provider, the complete list of medications (including any herbal supplements) you are currently taking. This will help the healthcare provider interpret your test results more accurately and avoid unnecessary chances of a misdiagnosis.

What are some Useful Resources for Additional Information?

Please visit our Laboratory Procedures Center for more physician-approved health information:

http://www.dovemed.com/common-procedures/procedures-laboratory/

References and Information Sources used for the Article:

https://ghr.nlm.nih.gov/primer/testing/genetictesting (accessed on 05/10/2017)

https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5806a1.htm (accessed on 05/10/2017)

http://www.nature.com/gim/journal/v10/n5/full/gim200852a.html (accessed on 05/10/2017)

http://pediatrics.aappublications.org/content/106/6/1494 (accessed on 05/10/2017)

OMIM Entry - # 604173 - POIKILODERMA WITH NEUTROPENIA; PN. (n.d.). Retrieved from http://www.omim.org/entry/604173

Shchepachev, V., Wischnewski, H., Missiaglia, E., Soneson, C., & Azzalin, C. (2012). Mpn1, Mutated in Poikiloderma with Neutropenia Protein 1, Is a Conserved 3′-to-5′ RNA Exonuclease Processing U6 Small Nuclear RNA. Cell Reports, 2(4), 855-865. doi:10.1016/j.celrep.2012.08.031

Helpful Peer-Reviewed Medical Articles:

Carrano, A. V., et al. Measurement and purification of human chromosomes by flow cytometry and sorting. Proceedings of the National Academy of Sciences 76, 1382–1384 (1979)

Drets, M. E., & Shaw, M. W. Specific banding patterns of human chromosomes. Proceedings of the National Academy of Sciences 68, 2073–2077 (1971)

Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31–36 (2002)

Parra, I., & Windle, B. High resolution visual mapping of stretched DNA by fluorescent hybridization. Nature Genetics 5, 17–21 (1993) doi:10.1038/ng0993-17

Pinkel, D., et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genetics 20, 207–211 (1998) doi:10.1038/2524

Speicher, M. R., et al. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nature Genetics 12, 368–375 (1996) doi:10.1038/ng0496-368

Makishima, H., Jankowska, A. M., McDevitt, M. A., O'Keefe, C., Dujardin, S., Cazzolli, H., ... & Shaik, M. (2011). CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood, blood-2010.

Tefferi, A., Jimma, T., Sulai, N. H., Lasho, T. L., Finke, C. M., Knudson, R. A., ... & Pardanani, A. (2012). IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia, 26(3), 475-480.

Shchepachev, V., Wischnewski, H., Missiaglia, E., Soneson, C., & Azzalin, C. M. (2012). Mpn1, mutated in poikiloderma with neutropenia protein 1, is a conserved 3′-to-5′ RNA exonuclease processing U6 small nuclear RNA. Cell reports, 2(4), 855-865.

Jekarl, D. W., Han, S. B., Kim, M., Lim, J., Oh, E. J., Kim, Y., ... & Han, K. (2010). JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia. The Korean journal of hematology, 45(1), 46-50.

Flach, J., Dicker, F., Schnittger, S., Kohlmann, A., Haferlach, T., & Haferlach, C. (2010). Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. haematologica, 95(3), 518-519.

Muendlein, A., Gasser, K., Kinz, E., Stark, N., Leiherer, A., Rein, P., ... & Lang, A. H. (2014). Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients. American journal of hematology, 89(3), 295-301.

Reviewed and Approved by a member of the DoveMed Editorial Board
First uploaded: May 29, 2017
Last updated: May 29, 2017